Transformation Into Viatris Not Seen As The Solution Mylan Needs
Analysts Remain Concerned About Growth Prospects
Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.
